Recombinant Human Neuregulin-2/NRG2 Fc Chimera Protein, CF

Recombinant Human Neuregulin-2/NRG2 Fc Chimera Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: Neuregulin-2/NRG2

Neuregulins (NRGs) are a family of six related physiological ligands all containing a receptor-binding epidermal growth factor (EGF)-like domain that mediate their binding to cellular receptors. The EGF-like domain is responsible for binding to the HER RTK family members (EGFR, HER2, HER3, and HER4). Human NRG2, also known as NTAK (neural-and thymus-derived activator for ErbB kinases), is a ~92 kDa, 850 aa protein composed of a 111 aa signal sequence, 294 aa extracellular domain, 21 aa transmembrane domain, and a 424 aa cytoplasmic domain. Human NRG2 shares 95% homology with mouse and rat NRG. NRG-2 encodes six to eight isoforms that contain Ig-like domains near their N-termini. The NRG family are involved in the development of the nervous and cardiovascular systems through the ErbB signaling pathway (1). They also regulate multiple intercellular signal transduction and a wide range of biological processes, such as differentiation, migration, and myelination (2). The primary receptor for NRG-2 is HER4, but binds directly to both ErbB3 and ErbB4, and transactivates ErbB1 and ErbB2 via heterodimerization with ErbB3 or ErbB4 (3, 4). Interaction between NRGs and their receptors plays an important role in the pathogenesis and treatment of neurodegenerative diseases (5). NRGs can be used as targets for therapeutic or clinical trials for their multiple roles in many neurological disorders, such as ALS, brain trauma, spinal cord injury, peripheral neuropathy, and schizophrenia (2). NRG-2 promotes neuronal survival when bound to ErbB3 on neurons (6). NRG-2 can indirectly transactivate HER2 and trigger downstream signaling pathways linked to carcinogenesis, tumor progression, and resistance to cancer therapies (7). NRG-2 binds to HER3 and HER4 to mediate downstream signaling linked to breast cancer initiation and progression (8, 9).

Related Research Areas

• EGF Family
• EGF Ligands